ChromaDex (CDXC) News Today

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

$3.69

-0.10 (-2.64%)

(As of 04/19/2024 ET)

Source

Source	Headline
	ChromaDex (CDXC) Price Target Increased by 9.92% to 6.60 msn.com - April 17 at 9:01 PM
	Short Interest in ChromaDex Co. (NASDAQ:CDXC) Grows By 12.8% marketbeat.com - April 14 at 11:34 PM
	ChromaDex (NASDAQ:CDXC) Price Target Increased to $6.00 by Analysts at Roth Mkm americanbankingnews.com - April 10 at 4:24 AM
	ChromaDex (NASDAQ:CDXC) PT Raised to $6.00 marketbeat.com - April 9 at 10:13 AM
	3 Chemical Stocks Poised for Gains stocknews.com - March 27 at 5:01 PM
	ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program businesswire.com - March 26 at 8:32 AM
	Short Interest in ChromaDex Co. (NASDAQ:CDXC) Declines By 9.0% marketbeat.com - March 19 at 3:32 PM
	Equities Analysts Offer Predictions for ChromaDex Co.'s FY2025 Earnings (NASDAQ:CDXC) marketbeat.com - March 14 at 7:36 AM
	ChromaDex Full Year 2023 Earnings: EPS Beats Expectations finance.yahoo.com - March 8 at 8:50 AM
	ChromaDex Co. Forecasted to Earn Q1 2025 Earnings of $0.01 Per Share (NASDAQ:CDXC) marketbeat.com - March 8 at 7:22 AM
	Persona 3 Reload is getting the DLC it needs, but not the one it deserves uk.sports.yahoo.com - March 8 at 1:24 AM
	ChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 7 at 3:23 PM
	ChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results with Positive Adjusted EBITDA finance.yahoo.com - March 7 at 3:23 PM
	What Wall Street expects from ChromaDex's earnings markets.businessinsider.com - March 6 at 11:44 PM
	CDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023 investorplace.com - March 6 at 11:01 PM
	Earnings Preview For ChromaDex benzinga.com - March 6 at 6:44 PM
	ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results finance.yahoo.com - March 6 at 6:44 PM
	Insiders own 26% of ChromaDex Corporation (NASDAQ:CDXC) shares but retail investors control 44% of the company finance.yahoo.com - March 2 at 12:51 PM
	ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024 finance.yahoo.com - February 21 at 12:29 PM
	ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024 businesswire.com - February 21 at 8:32 AM
	Top 3 Accelerating Chemical Stocks to Consider entrepreneur.com - February 6 at 10:27 AM
	ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024 finance.yahoo.com - February 5 at 1:35 PM
	ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference finance.yahoo.com - January 26 at 6:46 PM
	ChromaDex: Growth At A Reasonable Price seekingalpha.com - January 24 at 4:54 PM
	ChromaDex Corporation's (NASDAQ:CDXC) Shift From Loss To Profit finance.yahoo.com - January 19 at 9:29 AM
	ChromaDex (NASDAQ:CDXC) Upgraded at StockNews.com marketbeat.com - December 29 at 1:06 AM
	ChromaDex Supports the US Military with its Industry Leading NAD + Supplement, Tru Niagen businesswire.com - December 20 at 3:28 PM
	ChromaDex Flat on Assistance to Military baystreet.ca - December 20 at 10:28 AM
	ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen® finance.yahoo.com - December 20 at 10:28 AM
	A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD) finance.yahoo.com - November 30 at 3:43 PM
	An Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 44% Undervalued finance.yahoo.com - November 28 at 10:24 AM
	Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor ... businesswire.com - November 15 at 12:47 PM
	Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients finance.yahoo.com - November 15 at 12:47 PM
	ChromaDex Corporation (NASDAQ:CDXC) Q3 2023 Earnings Call Transcript finance.yahoo.com - November 10 at 4:40 PM
	Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Chromadex (CDXC) and Glaukos (GKOS) markets.businessinsider.com - November 10 at 6:38 AM
	ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023 finance.yahoo.com - November 9 at 12:39 PM
	ChromaDex GAAP EPS of -$0.01 beats by $0.02, revenue of $19.49M misses by $0.88M msn.com - November 8 at 9:06 PM
	ChromaDex: Q3 Earnings Insights benzinga.com - November 8 at 9:06 PM
	ChromaDex Corporation Reports Third Quarter 2023 Financial Results finance.yahoo.com - November 8 at 9:06 PM
	ChromaDex Corp (CDXC) Reports Growth in Net Sales and Positive Adjusted EBITDA in Q3 2023 finance.yahoo.com - November 8 at 9:06 PM
	Earnings Outlook For ChromaDex benzinga.com - November 7 at 2:32 PM
	ChromaDex Debuts Clinical Strength Tru Niagen ® Pro 1,000mg Featuring Niagen ® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide ... businesswire.com - November 1 at 3:53 PM
	ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide finance.yahoo.com - November 1 at 9:55 AM
	ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 finance.yahoo.com - October 31 at 1:31 PM
	Zesty Paws® & ChromaDex Crack the Code on Cellular Health for Dogs With 'Healthy Aging' Line finance.yahoo.com - October 27 at 8:11 PM
	ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line finance.yahoo.com - October 26 at 12:58 PM
	A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients finance.yahoo.com - October 2 at 1:50 PM
	Why Investors Are Flocking to These 3 Chemical Stocks? stocknews.com - September 18 at 9:06 PM
	Insider Stock Buying Reaches US$1.3m On ChromaDex finance.yahoo.com - September 3 at 6:11 PM
	Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More ... businesswire.com - August 24 at 3:31 PM

Get ChromaDex News Delivered to You Automatically

Secret Bull Market Starts in This Unusual Sector (Ad)

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

CDXC Media Mentions By Week

CDXC Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CDXC
News Sentiment
▼
1.24

0.52
▲
Average
Medical
News Sentiment

CDXC News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CDXC Articles
This Week
▼
2

1
▲
CDXC Articles
Average Week

Get ChromaDex News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:CDXC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ChromaDex (CDXC) News Today

CDXC Media Mentions By Week

CDXC Media Sentiment

CDXC News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info